TAXANES FOR OVARIAN CANCER: UPDATE
An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer
Background
The aim of this systematic review is to update the previous systematic review by bringing together the most recent reliable data to elucidate the following area of uncertainty: the use of paclitaxel as first-line treatment of ovarian cancer.Findings
The evidence does not appear to support the use of paclitaxel as first-line therapy for advanced ovarian cancer, and may provide a case for considering the use of carboplatin as first-line treatment for advanced ovarian cancer, rather than taxanes.
Conducted by: CRD